Loading clinical trials…
Loading clinical trials…
Clinical trials · failure tracking
Oncology studies whose overall status is TERMINATED, WITHDRAWN or SUSPENDED on ClinicalTrials.gov, with the stop reason exactly as the registrant posted it. A category is attached only when an explicit keyword rule matches the text; CancerIndex never infers why a study stopped.
2,127 stopped studies mapped to Secondary Malignant Neoplasm and descendants · 91% state a reason
Over the 2,127 studies matching the cancer, status and year filters (the category filter does not change this chart). Each study is counted once, in the first matching category; greyed bars are studies whose text matched no rule or was empty.
Computedrules ci-stop-reasons-v1 · keyword matching only
A category is assigned when one of its keywords appears in the posted text (case-insensitive, whole words). Rules are tested in this order and the first match wins; every match is kept in the API (reasonMatches).
| NCT | Title | Phase | Status | First posted | Lead sponsor | Why stopped (as posted) | Category |
|---|---|---|---|---|---|---|---|
| NCT06365918 | Study of VG2025 Delivered Intraperitoneally in Patients With Advanced Solid Tumors With… | Phase 1 | withdrawn | Apr 15, 2024 | M.D. Anderson Cancer Center | PI Request | Other (stated, no rule matched) |
| NCT03013946 | Role of PRoactivE Coaching on PAtient REported Outcome in Advanced or Metastatic RCC…(PREPARE) | Phase 3 | terminated | Jan 9, 2017 | AIO-Studien-gGmbH | insufficient accrual rate | Enrollment / accrual |
| NCT04588038 | NT-I7 for the Treatment of Recurrent Squamous Cell Carcinoma of Head and Neck Undergoing… | Phase 1 | terminated | Oct 19, 2020 | Hyunseok Kang, MD | Slow Accrual | Enrollment / accrual |
| NCT03822936 | Carbon Ions Radiation Therapy for Resectable or Borderline Resectable Pancreas…(PIOPPO) | Phase 2 | terminated | Jan 30, 2019 | CNAO National Center of Oncological Hadrontherapy | The study was early closed due to low accrual in August 2022. | Enrollment / accrual |
| NCT04906382 | Tislelizumab for the Treatment of Recurrent Mismatch Repair Deficient Endometrial Cancer | Early Phase 1 | terminated | May 28, 2021 | Floor Backes, MD | Sponsor reorganization | Other (stated, no rule matched) |
| NCT01205828 | ABT-888 and Temozolomide for Liver Cancer | Phase 2 | terminated | Sep 21, 2010 | Georgetown University | Lack of efficacy | Efficacy / futility |
| NCT04254107 | A Safety Study of SEA-TGT (SGN-TGT) in Advanced Cancer | Phase 1 | terminated | Feb 5, 2020 | Seagen Inc. | Study closed due to portfolio prioritization | Sponsor / business decision |
| NCT04432532 | Neuroendocrine and Adrenal Tumors(NETAT) | — | withdrawn | Jun 16, 2020 | University of Pennsylvania | Change in research direction | Other (stated, no rule matched) |
| NCT04862780 | (SYMPHONY) Phase 1/2 Study Targeting EGFR Resistance Mechanisms in NSCLC | Phase 1 | terminated | Apr 28, 2021 | Blueprint Medicines Corporation | Sponsor decision, not related to safety concerns | Safety / toxicity |
| NCT05241873 | (Concerto) Study of BLU-451 in Advanced Cancers With EGFR Exon 20 Insertion Mutations | Phase 1 | terminated | Feb 16, 2022 | Blueprint Medicines Corporation | Sponsor decision, not related to safety concerns | Safety / toxicity |
| NCT04665921 | A Study of SGN-STNV in Advanced Solid Tumors | Phase 1 | terminated | Dec 14, 2020 | Seagen Inc. | Study closed due to portfolio prioritization | Sponsor / business decision |
| NCT05296005 | Neoadjuvant Therapy for the Treatment of Gastroesophageal Junction and Gastric Cancers | Phase 1 | withdrawn | Mar 25, 2022 | Ohio State University Comprehensive Cancer Center | PI Decision | Other (stated, no rule matched) |
| NCT05631574 | Study of Covalent Menin Inhibitor BMF-219 in Adult Patients With KRAS Driven Non-Small… | Phase 1 | terminated | Nov 30, 2022 | Biomea Fusion Inc. | Biomea Fusion, Inc., is no longer pursuing oncology indications for BMF-219. No safety concerns or… | Safety / toxicity |
| NCT02935478 | Bariatric Embolization of Arteries in Obese Patients With HCC to Allow Salvage Liver… | N/A | suspended | Oct 17, 2016 | St. Louis University | IRB reviewing study conduct and adverse events | Safety / toxicity |
| NCT06702384 | Molecular Analysis of Gastric and OEsophageal Cancers STudy(MAGnET) | — | withdrawn | Nov 25, 2024 | Royal Marsden NHS Foundation Trust | Never opened to recruitment due to lack of funding | Enrollment / accrual |
| NCT03371381 | An Efficacy and Safety Study of JNJ-64041757, a Live Attenuated Listeria Monocytogenes… | Phase 1 / Phase 2 | terminated | Dec 13, 2017 | Janssen Research & Development, LLC | Development of JNJ-64041757 in combination with nivolumab discontinued due to lack of clinical… | Efficacy / futility |
| NCT05497453 | A Phase 1/2 Study to Evaluate OTX-2002 in Patients with Hepatocellular Carcinoma and…(MYCHELANGELO I) | Phase 1 / Phase 2 | terminated | Aug 11, 2022 | Omega Therapeutics | Sponsor decision to terminate after monotherapy dose escalation. | Sponsor / business decision |
| NCT03736720 | Liposomal Irinotecan, Fluorouracil and Leucovorin in Treating Patients With Refractory… | Phase 2 | terminated | Nov 9, 2018 | Roswell Park Cancer Institute | low accrual | Enrollment / accrual |
| NCT05113966 | Trilaciclib in Patients Receiving Sacituzumab Govitecan-hziy for Triple Negative Breast… | Phase 2 | terminated | Nov 9, 2021 | G1 Therapeutics, Inc. | The Sponsor decided to close enrollment to the study on Feb 14, 2023, in order to reallocate… | Enrollment / accrual |
| NCT05539365 | Dendritic Cell-Based Treatment Plus Immunotherapy for the Treatment of Metastatic or… | Phase 2 | withdrawn | Sep 14, 2022 | Roswell Park Cancer Institute | Study never activated. | Other (stated, no rule matched) |
| NCT05845502 | Single-arm, Open-label Clinical Study of SZ003 in the Treatment of Advanced… | N/A | terminated | May 6, 2023 | Shantou University Medical College | Failed to recruit more volunteers | Enrollment / accrual |
| NCT05457478 | The Use of "Smart" Body-Weight Scales for Weight and Nutritional Monitoring in Patients… | N/A | terminated | Jul 14, 2022 | OHSU Knight Cancer Institute | PI departure | Other (stated, no rule matched) |
| NCT06341647 | Phase 1 Clinical Trial to Evaluate the Safety and Anti-Tumor Activity of AB-201 | Phase 1 | withdrawn | Apr 2, 2024 | GC Cell Corporation | Determined that enrollment would be limited due to the change in care setting. | Enrollment / accrual |
| NCT02485834 | FDG-PET Directed Treatment in Improving Response in Patients With Locally Advanced… | Phase 2 | terminated | Jun 30, 2015 | Alliance for Clinical Trials in Oncology | Poor accrual | Enrollment / accrual |
| NCT05534789 | Treatment Patterns and Clinical Outcomes Among Patients With Advanced Renal Cell… | — | terminated | Sep 10, 2022 | Pfizer | The trial prematurely terminated due to the inability to recruit the planned number of… | Safety / toxicity |
| NCT06206876 | FL118 for Treating Patients With Advanced Pancreatic Ductal Adenocarcinoma | Phase 1 | withdrawn | Jan 16, 2024 | Roswell Park Cancer Institute | never opened | Other (stated, no rule matched) |
| NCT05776875 | Atezolizumab and Bevacizumab in Combination With TACE for Patients With BCLC B HCC | Phase 2 | terminated | Mar 20, 2023 | Yale University | Low enrollment | Enrollment / accrual |
| NCT02489604 | Peptide Receptor Radionuclide Therapy (PRRT) with 177Lu-DOTATATE in Advanced…(LUNET) | Phase 2 | terminated | Jul 3, 2015 | Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS | Enrollment target not reached | Enrollment / accrual |
| NCT04066660 | Study of Oligo-Fucoidan in Advanced Hepatocellular Carcinoma (HCC) | N/A | terminated | Aug 26, 2019 | Hi-Q Marine Biotech International, Ltd. | After interim analysis, we planned to recruit 100 participants. However, due to COVID-19… | COVID-19 / pandemic |
| NCT05653427 | A Study of Amivantamab Monotherapy in Participants With Previously Treated Advanced… | Phase 2 | terminated | Dec 16, 2022 | Janssen Research & Development, LLC | N\~15 subjects data analysis did not meet statistical consideration of ORR and study… | Efficacy / futility |
| NCT04162665 | Pre-operative Adaptive Short Court Radiation Therapy in Gastric Cancer | Phase 2 | terminated | Nov 14, 2019 | Washington University School of Medicine | Poor accrual and funding sponsor declared bankruptcy. | Enrollment / accrual |
| NCT04438083 | A Safety and Efficacy Study Evaluating CTX130 in Subjects With Relapsed or Refractory… | Phase 1 | terminated | Jun 18, 2020 | CRISPR Therapeutics AG | Patients to be followed up in the CRSP-ONC-LTF study | Other (stated, no rule matched) |
| NCT02671890 | Disulfiram and Chemotherapy in Treating Patients With Refractory Solid Tumors or… | Phase 1 | terminated | Feb 2, 2016 | Mayo Clinic | lack of funding | Funding |
| NCT04951492 | Olaparib for the Treatment of Castration Resistant Prostate Adenocarcinoma | Phase 2 | terminated | Jul 6, 2021 | University of Washington | Withdrawal of funding | Funding |
| NCT04923776 | Liver Directed RT + Chemo-immunotherapy for ES-SCLC | Phase 2 | terminated | Jun 11, 2021 | Brian Henick, MD | Poor enrollment | Enrollment / accrual |
| NCT04807777 | Study of Ruxolitinib in Solid Organ Transplant Recipients With Advanced Cutaneous… | Phase 2 | terminated | Mar 19, 2021 | Columbia University | Departure of the original investigator | Investigator |
| NCT05500508 | Oral AMXT 1501 Dicaprate in Combination With IV DFMO | Phase 1 / Phase 2 | terminated | Aug 15, 2022 | Aminex Therapeutics, Inc. | Required re-formulation of DFMO from IV to capsule to maintain safety | Safety / toxicity |
| NCT05289648 | Niraparib in High-grade Endometrial Cancer Trial(NIREC) | Early Phase 1 | withdrawn | Mar 21, 2022 | Sir Mortimer B. Davis - Jewish General Hospital | Unable to obtain funding | Funding |
| NCT05546411 | A Trial of NIS793 With FOLFIRINOX in Pancreatic Cancer | Phase 2 | terminated | Sep 19, 2022 | Kimberly Perez, MD | Novartis, the drug manufacturer of NIS793, notified Dana Farber Cancer Institute that they are… | Drug supply |
| NCT05555251 | BI-1607 in Combination with Trastuzumab in Subjects with HER2-positive Advanced Solid…(CONTRAST) | Phase 1 / Phase 2 | terminated | Sep 26, 2022 | BioInvent International AB | After the completion of phase IA, for business reasons it was decided to terminate the study. | Sponsor / business decision |
| NCT03549000 | A Phase I/Ib Study of NZV930 Alone and in Combination With PDR001 and /or NIR178 in… | Phase 1 | terminated | Jun 7, 2018 | Novartis Pharmaceuticals | After review of data which showed low likelihood of efficacy in these patients Novartis decided to… | Safety / toxicity |
| NCT03473691 | Pilot Study of Glembatumumab Vedotin Following Doxorubicin and Cytoxan as Neo-adjuvant…(Breast50) | Early Phase 1 | withdrawn | Mar 22, 2018 | University of Virginia | Pharmaceutical company decided to withdraw funding and not provide drug. | Funding |
| NCT05999292 | Phase 1 Study of 68Ga-R8760 | Phase 1 | terminated | Aug 21, 2023 | Radionetics Oncology | Sponsor decision | Sponsor / business decision |
| NCT05049863 | Chemotherapy in Patients With Relapsed Small Cell Lung Cancer in Combination With… | Phase 1 | terminated | Sep 20, 2021 | Washington University School of Medicine | Futility | Efficacy / futility |
| NCT05119010 | A Pilot Study Evaluating a Ketogenic Diet Concomitant to Nivolumab and Ipilimumab in…(KETOREIN) | N/A | terminated | Nov 12, 2021 | Gustave Roussy, Cancer Campus, Grand Paris | Recruitment challenges: competition with another microbiome trial, patient refusal to join a… | Enrollment / accrual |
| NCT04675827 | De-escalation Adjuvant Chemo in HER2+/ER-/node-neg Early BC Patients Who Achieved PCR…(Decrescendo) | Phase 2 | terminated | Dec 19, 2020 | Jules Bordet Institute | Serious concerns on the slow recruitment of the study that impacts the robustness of the scientific… | Enrollment / accrual |
| NCT05744128 | CD8 Minibody Repeatability Study(PRETZCEL) | Phase 2 | terminated | Feb 24, 2023 | ImaginAb, Inc. | Strategic decision | Sponsor / business decision |
| NCT04951115 | A Trial With Chemotherapy, Immunotherapy, and Radiotherapy for Patients With Newly… | Phase 2 | terminated | Jul 6, 2021 | Weill Medical College of Cornell University | The study was terminated early due to low accrual. | Enrollment / accrual |
| NCT04985357 | Defining the Clinical Potential of Mass Response As a Biomarker for Patient Tumor… | — | withdrawn | Aug 2, 2021 | Travera Inc | Abandoned prior to launch. | Other (stated, no rule matched) |
| NCT05418387 | A Social Support Intervention to Improve Treatment Among Hispanic Kidney and Liver Cancer… | N/A | withdrawn | Jun 14, 2022 | University of Arizona | The study will be withdrawn as the Principal Investigator, Ken Batai, left the institution prior to… | Investigator |
Stop reasons are registrant-reported free text and are displayed verbatim (truncated; hover for the full text). Categories come from explicit keyword rules and are never inferred from the study design, sponsor or outcome; a study that stopped for several reasons is filed under the first rule that matched. A TERMINATED status does not imply a negative result.
Data updated 24 days agoSource updated Feb 17, 2025source: clinicaltrials